Drug survival of biologic agents for psoriatic patients in a real-world setting in Japan.
biologics
drug survival
generalized pustular psoriasis
psoriasis
treatment
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
08
09
2019
accepted:
15
10
2019
pubmed:
7
11
2019
medline:
26
9
2020
entrez:
8
11
2019
Statut:
ppublish
Résumé
This is a Japanese retrospective single-center study carried out between 1 January 2010 and 21 November 2018 at the Department of Dermatology in Jichi Medical University Hospital. The drug survival rate for six biologic agents used for the treatment of psoriasis was investigated. We reviewed the clinical records of 315 treatment series of 205 patients with moderate to severe psoriasis treated with adalimumab (103 cases), infliximab (70 cases), ustekinumab (66 cases), secukinumab (38 cases), brodalumab (12 cases) and ixekizumab (26 cases). In our study, ustekinumab revealed a trend towards higher drug survival among the six biologic agents. Ustekinumab had a higher drug survival rate than infliximab and secukinumab with significant differences by log-rank test among all patients and among biologic-naive (bio-naive) patients. There was no significant difference in drug survival between bio-naive and biologic-experienced (non-naive) patients in the treatment courses with adalimumab, infliximab, ustekinumab, secukinumab and ixekizumab. The dose augmentation therapy in infliximab-treated patients was associated with longer drug survival. Of all patients, 25 cases with generalized pustular psoriasis (GPP) were included, who functioned as the negative predictor for drug persistence with a hazard ratio of 1.87 (95% confidence interval, 1.12-3.11; P = 0.016). Our results reveal that ustekinumab had a superior drug survival, which is supported by the previous studies. Further studies are needed to clarify the efficacy of biologic agents on patients with GPP.
Identifiants
pubmed: 31696543
doi: 10.1111/1346-8138.15146
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Biological Products
0
Types de publication
Comparative Study
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
33-40Informations de copyright
© 2019 Japanese Dermatological Association.
Références
Reich K, Wozel G, Zheng H, van Hoogstraten HJ, Flint L, Barker J. Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2). Br J Dermatol 2013; 168: 1325-1234.
Gordon K, Papp K, Poulin Y, Gu Y, Rozzo S, Sasso EH. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol 2012; 66: 241-51.
Langley RG, Lebwohl M, Krueger GG et al. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. Br J Dermatol 2015; 172: 1371-1383.
Bissonnette R, Luger T, Thaçi D et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol 2018; 32: 1507-1514.
Papp KA, Reich K, Paul C et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 2016; 175: 273-286.
Leonardi C, Maari C, Philipp S et al. Maintenance of skin clearance with ixekizumab treatment of psoriasis: three-year results from the UNCOVER-3 study. J Am Acad Dermatol 2018; 79: 824-830.e2.
van den Reek JMPA, Kievit W, Gniadecki R et al. Drug survival studies in dermatology: principles, purposes, and pitfalls. J Invest Dermatol 2015; 135: 1-5.
Costanzo A, Malara G, Pelucchi C et al. Effectiveness end points in real-world studies on biological therapies in psoriasis: systematic review with focus on drug survival. Dermatology 2018; 234: 1-12.
Menter A, Papp KA, Gooderham M et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol 2016; 30: 1148-1158.
Vilarrasa E, Notario J, Bordas X, López-Ferrer A, Gich IJ, Puig L. ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): a retrospective observational study on biologic drug survival in daily practice. J Am Acad Dermatol 2016; 74: 1066-1072.
Roche H, Bouiller K, Puzenat E et al. Efficacy and survival of biologic agents in psoriasis: a practical real-life 12-year experience in a French dermatology department. J Dermatolog Treat 2018; 31: 1-17.
Torres T, Filipe P, Basto AS et al. The DRAGON study: biologic DRug survivAl in PortuGuese psOriasis patieNts. Eur J Dermatol 2018; 28: 685-687.
No DJ, Inkeles MS, Amin M, Wu JJ. Drug survival of biologic treatments in psoriasis: a systematic review. J Dermatolog Treat 2018; 29: 460-466.
Lin PT, Wang SH, Chi CC. Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence. Sci Rep 2018; 8: 16068.
Egeberg A, Ottosen MB, Gniadecki R et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol 2018; 178: 509-519.
Lunder T, Zorko MS, Kolar NK et al. Drug survival of biological therapy is showing class effect: updated results from Slovenian National Registry of psoriasis. Int J Dermatol 2019; 58: 631-641.
Mourad A, Straube S, Armijo-Olivo S, Gniadecki R. Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis. Br J Dermatol 2019; 181: 450-458.
Kamiya K, Karakawa M, Komine M, Kishimoto M, Sugai J, Ohtsuki M. Results of a retrospective study on the efficacy and safety of adalimumab 80 mg administrated every other week in patients with psoriasis at a single Japanese institution. J Dermatol 2019; 46: 199-205.
Ohtsuki M, Terui T, Ozawa A et al. Japanese guidance for use of biologics for psoriasis (the 2013 version). J Dermatol 2013; 40: 683-695.
Lee EB, Amin M, Egeberg A, Wu JJ. Drug survival of secukinumab for psoriasis in a real-world setting. J Dermatolog Treat 2019; 30: 150-151.
Egeberg A, Bryld LE, Skov L. Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2019; 81: 173-178.
van den Reek JMPA, van Vugt LJ, van Doorn MBA et al. Initial results of secukinumab drug survival in patients with psoriasis: a multicentre daily practice cohort study. Acta Derm Venereol 2018; 98: 648-654.
Torres T, Balato A, Conrad C et al. Secukinumab drug survival in patients with psoriasis: a multicenter, real-world, retrospective study. J Am Acad Dermatol 2019; 81: 273-275.
Augustin M, Thaci D, Eyerich K et al. Continued treatment with secukinumab is associated with high retention or regain of response. Br J Dermatol 2019. https://doi.org/10.1111/bjd.17991